Tocilizumab as an Effective Treatment Option in Children with Refractory Intermediate and Panuveitis.

Conclusion: Tocilizumab is an effective therapeutic option for reducing disease activity in children with refractory non-anterior uveitis. PMID: 32058831 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32058831?dopt=Abstract

Source: Ocular Immunology and Inflammation - February 16, 2020 Category: Allergy & Immunology Tags: Ocul Immunol Inflamm Source Type: research